Over the past 12 months, $ZYME has been mentioned 10 times by 2 distinct FinTwit voices, with the first mention appearing on 2025-10-19. The biotech sector voices dominate discussion, with @jacobplieth accounting for 9 of the 10 mentions, establishing him as the primary voice tracking the company. @investmentguru_ contributed 1 mention during this period. The most recent discussion occurred on 2026-06-29, with activity spanning from October 2025 through June 2026.

@jacobplieth's coverage of $ZYME has focused on the company's clinical pipeline, particularly pan-RAS inhibitor payload ADCs presented at AACR26 in May 2026. His posts have examined the therapeutic approach targeting RAS-mutated tumours expressing specific antigens including PTK7, Ly6E, and Claudin18.2. Commentary from @jacobplieth also referenced corporate development activity, with a June 2026 post noting deal structures associated with the company.